Enanta Pharmaceuticals Stock Alpha and Beta Analysis
| ENTA Stock | USD 12.38 0.09 0.72% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Enanta Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Enanta Pharmaceuticals over a specified time horizon. Remember, high Enanta Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Enanta Pharmaceuticals' market risk premium analysis include:
Beta 1.9 | Alpha (0.20) | Risk 4.01 | Sharpe Ratio (0.07) | Expected Return (0.29) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Enanta |
Enanta Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Enanta Pharmaceuticals market risk premium is the additional return an investor will receive from holding Enanta Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Enanta Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Enanta Pharmaceuticals' performance over market.| α | -0.2 | β | 1.90 |
Enanta Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Enanta Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Enanta Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Enanta Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Enanta Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Enanta Pharmaceuticals shares will generate the highest return on investment. By understating and applying Enanta Pharmaceuticals stock market price indicators, traders can identify Enanta Pharmaceuticals position entry and exit signals to maximize returns.
Enanta Pharmaceuticals Return and Market Media
The median price of Enanta Pharmaceuticals for the period between Wed, Mar 6, 2024 and Tue, Jun 4, 2024 is 14.0 with a coefficient of variation of 11.09. The daily time series for the period is distributed with a sample standard deviation of 1.58, arithmetic mean of 14.23, and mean deviation of 1.36. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Foletta Mark G of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3 | 03/22/2024 |
2 | Brokerages Set Enanta Pharmaceuticals, Inc. Target Price at 19.33 - Defense World | 03/28/2024 |
3 | Assenagon Asset Management S.A. Sells 47968 Shares of Enanta Pharmaceuticals, Inc. - Defense World | 04/01/2024 |
4 | Vanguard Group Inc. Decreases Stock Position in Enanta Pharmaceuticals, Inc. - Defense World | 04/15/2024 |
5 | Insider Trading | 04/29/2024 |
6 | Trading With Integrated Risk Controls - Stock Traders Daily | 04/30/2024 |
7 | Acquisition by Paul Mellett of 10440 shares of Enanta Pharmaceuticals at 14.0 subject to Rule 16b-3 | 05/01/2024 |
8 | ENTA Stock Earnings Enanta Pharma Misses EPS, Beats Revenue for Q2 2024 - MSN | 05/06/2024 |
9 | Analysts Offer Predictions for Enanta Pharmaceuticals, Inc.s Q1 2025 Earnings - MarketBeat | 05/09/2024 |
10 | Earnings Preview Enanta Pharmaceuticals Q3 Earnings Expected to Decline - Yahoo Singapore News | 05/14/2024 |
11 | Disposition of 1584 shares by Jay Luly of Enanta Pharmaceuticals at 12.41 subject to Rule 16b-3 | 05/31/2024 |
About Enanta Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Enanta or other stocks. Alpha measures the amount that position in Enanta Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 45.54 | 38.52 | 44.3 | 58.36 | Receivables Turnover | 1.76 | 2.0 | 2.3 | 2.18 |
Enanta Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Enanta Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Enanta Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Enanta Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Enanta Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Enanta Stock
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Enanta Pharmaceuticals Backtesting, Enanta Pharmaceuticals Valuation, Enanta Pharmaceuticals Correlation, Enanta Pharmaceuticals Hype Analysis, Enanta Pharmaceuticals Volatility, Enanta Pharmaceuticals History and analyze Enanta Pharmaceuticals Performance. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Enanta Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.